Androgen receptor variant-driven prostate cancer II: advances in clinical investigation
出版年份 2020 全文链接
标题
Androgen receptor variant-driven prostate cancer II: advances in clinical investigation
作者
关键词
-
出版物
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-02-25
DOI
10.1038/s41391-020-0215-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
- (2019) Adam Sharp et al. EUROPEAN UROLOGY
- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) James L. Mohler et al. Journal of the National Comprehensive Cancer Network
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
- (2019) Bram De Laere et al. JAMA Oncology
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
- (2019) Matthew D. Tucker et al. Cancer Medicine
- Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer
- (2019) Mary-Ellen Taplin et al. EUROPEAN UROLOGY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- 845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors
- (2019) E S Antonarakis et al. ANNALS OF ONCOLOGY
- 503PEPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
- (2019) R Le Moigne et al. ANNALS OF ONCOLOGY
- Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
- (2018) Jun Luo et al. EUROPEAN UROLOGY
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
- (2018) Benjamin A Teply et al. LANCET ONCOLOGY
- Bromodomain-containing proteins in prostate cancer
- (2018) Alfonso Urbanucci et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
- (2018) Michael T. Schweizer et al. PLoS One
- The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells
- (2018) Marie C. Hupe et al. WORLD JOURNAL OF UROLOGY
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- (2018) Karim Boudadi et al. Oncotarget
- Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
- (2018) Howard I. Scher et al. JAMA Oncology
- Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer
- (2018) Navid Sobhani et al. INVESTIGATIONAL NEW DRUGS
- Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
- (2018) Emmanuel S. Antonarakis NEW ENGLAND JOURNAL OF MEDICINE
- Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY
- (2018) Scott T Tagawa et al. CLINICAL CANCER RESEARCH
- Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
- (2018) Adam Sharp et al. JOURNAL OF CLINICAL INVESTIGATION
- Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
- (2018) Enrique González-Billalabeitia et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
- (2018) Markus Mayrhofer et al. Genome Medicine
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
- (2017) Howard I. Scher et al. EUROPEAN UROLOGY
- Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer
- (2017) Christof Bernemann et al. EUROPEAN UROLOGY
- Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
- (2017) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting
- (2017) Parvez M. Lokhandwala et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- The molecular biology of prostate cancer: current understanding and clinical implications
- (2017) Jason Gandhi et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
- (2016) Jun Luo ASIAN JOURNAL OF ANDROLOGY
- AR-V7 and prostate cancer: The watershed for treatment selection?
- (2016) Chiara Ciccarese et al. CANCER TREATMENT REVIEWS
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
- (2016) Emily J. Faivre et al. MOLECULAR CANCER RESEARCH
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
- (2016) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
- (2016) Christine Henzler et al. Nature Communications
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
- (2015) Lucas J. Brand et al. Oncotarget
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Detecting predictive androgen receptor modifications in circulating prostate cancer cells
- (2015) Oncotarget
- Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
- (2014) Maria Thadani-Mulero et al. CANCER RESEARCH
- Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer
- (2014) Z. Zhang et al. CANCER RESEARCH
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal
- (2012) Siu Chiu Chan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors
- (2008) R. Snoek et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search